By Marcus A. Banks
The Risk Evaluation and Mitigation Strategy (REMS) that specialty pharmacists employ for certain high-risk medications can be cumbersome and time-intensive, with manual entry requirements plus a lengthy process involving numerous stakeholders to prove that a drug will do more benefit than harm for a given patient, speakers noted at the NASP 2024 Annual Meeting & Expo, in Nashville, Tenn.
Ensuring REMS compliance is sometimes so laborious that a patient does not receive a